First Trust SMID Growth Strength ETF (FSGS) Stock Price

30.145 ▼ -0.0909 (-0.30%)
Open: 30.17 Vol: 900 Day's range: 30.14 - 30.17 Nov 14, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
FSGS Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 30.77▲ 30.77▲ 30.77▲ 30.49▼ 30.58▼
MA10 30.83▲ 30.83▲ 30.83▲ 30.45▼ 30.87▼
MA20 31.04▼ 31.10▼ 31.10▼ 30.72▼ 30.79▼
MA50 30.69▲ 30.25▲ 30.25▲ 31.02▼ N/A    
MA100 28.88▲ 28.80▲ 28.82▲ 30.81▼ N/A    
MA200 N/A     N/A     N/A     29.59▲ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.099▼ -0.130▼ -0.130▼ -0.024▼ -0.126▼
RSI 50.238▲ 51.510▲ 51.507▲ 41.011▼ 47.390▼
STOCH 49.937     49.937     49.937     47.966     22.076    
WILL %R -42.000     -42.000     -42.000     -91.732▼ -94.232▼
CCI -15.537     -15.537     -15.537     -93.264     -119.622▼
Latest Filters Detected On FSGS
▼ MACD $FSGS MACD(12,26,9) Crossed Below Signal Line Set Alert
MA $FSGS Price Crossed Below MA(13) Set Alert
MA $FSGS Price Crossed Below MA(7) Set Alert
CDL $FSGS Doji Candlestick Pattern Detected Set Alert
First Trust SMID Growth Strength ETF News
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come
Thursday, November 13, 2025 06:09 AM
Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025.
Amicus Therapeutics: Moving Towards Consistent Profitability
Tuesday, November 11, 2025 12:56 PM
Amicus Therapeutics' solid Q3 results, new pipeline additions, and global expansion signal strong growth potential. Read the latest analysis on the stock here.
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Thursday, November 06, 2025 08:11 AM
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® ...
FSGS historical stock data
date open high low close volume
14/11/25 30.17 30.17 30.14 30.145 900
13/11/25 30.2316 30.2359 30.2316 30.2359 255
12/11/25 30.82 30.89 30.782 30.782 600
11/11/25 30.575 30.809 30.575 30.71 1,800
10/11/25 30.55 30.68 30.55 30.575 3,907
07/11/25 30.085 30.337 30.04 30.337 700
06/11/25 30.15 30.23 30.15 30.166 1,500
05/11/25 30.41 30.698 30.41 30.69 1,300
04/11/25 30.25 30.421 30.25 30.421 4,511
03/11/25 30.12 30.439 30.112 30.439 1,700
Quote Details
52wk Low:24.39
52wk High:32.215
Vol:900
Avg Vol(3m):55.6K
1Y Chng:+0.00%
1M Chng:-3.52%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00